US Market Overview for Immunology Drugs 2018 - MedView

Tuesday, November 7, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 6, 2017 /PRNewswire/ -- The report is an extensive market analysis study on the current biologics such as

ORENCIA®, HUMIRA®, CIMZIA®, Enbrel®, SIMPONI®, REMICADE®, RITUXAN®, Actemra®, STELARA®, ENTYVIO® and TYSABRI ®. The others segment includes XELJANZ®, promising biologics in pipeline consisting of JAK inhibitors (imposing competition to XELJANZ®) and
other TNF and interleukin biologics that will enter the market during the forecast period.Read the full report: https://www.reportlinker.com/p05175231Some of these biologics are approved and used in more than one conditions. Therefore, the market is segmented by diseases. The report comprises market analyses on rheumatoid arthritis, ankylosing spondylitis, Crohn`s disease, ulcerative colitis and psoriasis drugs globally.AbstractThe U.S. immunology market includes biologic drugs that are used in the treatment of various immunology diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn`s disease (CD), ulcerative colitis (UC) and psoriasis (PsO). As there is a need for cost effective drugs in treating these diseases, there is an increased number of drugs in development for these diseases. Current treatment mainly constitutes NSAIDs and biologics. However, this report is limited to biologics, as they constitute 90% of the revenue in immunology. The reports covers second line treatments, their dosage, comparative cost studies, market size and revenue forecasts.Scope2014-2024Read the full report: https://www.reportlinker.com/p05175231 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. https://www.reportlinker.com __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/us-market-overview-for-immunology-drugs-2018---medview-300550588.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store